Company Overview

Microbot Medical Inc. is a medical technology company focused on the development of robotic and artificial intelligence-assisted platforms for minimally invasive endovascular procedures. The company operates within the medical device and surgical robotics industries, with a primary emphasis on robotic catheter navigation systems designed for interventional radiology, cardiology, and neurovascular applications. Its core strategy centers on improving procedural precision, reducing physician radiation exposure, and enabling remote-controlled endovascular interventions.

The company’s primary asset is the LIBERTY Endovascular Robotic System, a compact robotic platform intended to facilitate single-use, disposable robotic catheter procedures. Microbot Medical has also developed complementary technologies including the One & Done disposable robotic catheter platform and the TipCAT remote steerable catheter technology. The company historically evolved from earlier micro-robotics and imaging technology initiatives and has shifted over time toward commercializing robotic-assisted endovascular solutions targeting hospitals, ambulatory surgical centers, and interventional specialists. Public filings and investor materials indicate that the company’s strategic positioning emphasizes portability, lower infrastructure requirements relative to larger robotic systems, and potential compatibility with remote intervention capabilities.

Business Operations

Microbot Medical primarily operates through a single medical robotics and endovascular technology business segment. Revenue generation has historically been limited because the company remains in a developmental and pre-commercial stage, with operations focused largely on research and development, regulatory advancement, clinical validation, and intellectual property expansion. According to public filings, the company’s expenditures are concentrated on engineering, regulatory compliance, product testing, and clinical trial activities associated with the LIBERTY platform.

The company’s operational footprint includes activities in the United States and Israel, where portions of research, engineering, and technology development functions have historically been conducted. Microbot Medical controls multiple patents and proprietary robotic navigation technologies associated with endovascular procedures. The company has also entered collaborations with healthcare institutions and technology providers to support development and testing initiatives. Publicly disclosed relationships have included work with medical research organizations and imaging integration efforts intended to enhance procedural guidance and remote operation capabilities.

Strategic Position & Investments

Microbot Medical’s strategic direction is centered on obtaining regulatory clearance for the LIBERTY Endovascular Robotic System and positioning the platform within the growing robotic-assisted surgery and interventional procedure market. Company disclosures indicate a focus on expanding clinical validation, integrating artificial intelligence-assisted workflow capabilities, and pursuing commercialization opportunities in minimally invasive vascular interventions. Management has identified reduced radiation exposure, physician ergonomics, and procedural standardization as key market drivers supporting adoption of robotic endovascular systems.

The company has invested substantially in intellectual property development, robotic catheter engineering, and disposable robotic device technologies. Microbot Medical has also pursued strategic technology enhancements through internal development and acquired technologies associated with catheter navigation and robotic control systems. Its broader positioning reflects participation in emerging sectors including remote robotic intervention, telemedicine-enabled procedures, and AI-assisted surgical robotics. Public information indicates that the company continues to evaluate partnerships and commercialization arrangements intended to support future market entry and clinical adoption.

Geographic Footprint

Microbot Medical is headquartered in Massachusetts, United States, with historical operational and development ties to Israel. Its activities primarily target the North American healthcare market, particularly the United States interventional medicine sector, where regulatory approval and commercialization efforts are concentrated. The company’s filings also reference international intellectual property protections and global market opportunities for robotic-assisted vascular procedures.

Although commercial operations remain limited due to the company’s development-stage status, Microbot Medical’s technology strategy is designed for potential deployment across hospitals and interventional centers in multiple international regions, including Europe, Asia-Pacific, and the Middle East. Public disclosures indicate that future growth plans may involve international distribution partnerships and broader regulatory expansion outside the United States following additional clinical and regulatory milestones.

Leadership & Governance

Microbot Medical’s leadership team combines experience in medical devices, healthcare commercialization, finance, and robotic technologies. Corporate governance oversight is provided through its executive leadership and board of directors, with strategic emphasis on regulatory advancement, product commercialization, and long-term shareholder value creation.

Key executives include:

• Harel Gadot – Chairman, President and Chief Executive Officer
• Yossi Bornstein – Chief Financial Officer
• Ronen Feldman – Vice President of Research and Development
• Benny Grossman – Vice President of Regulatory and Clinical Affairs

Management communications and public filings indicate that leadership’s strategic vision is focused on advancing robotic-assisted endovascular intervention technologies that may improve procedural accessibility, physician safety, and operational efficiency. The company’s governance framework and disclosures are documented through SEC filings, including annual reports and investor presentations.